Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support

In a patient with nephrotic syndrome, renal biopsy revealed AL amyloid deposits. Monoclonal lambda light chains were identified in serum and urine. A low percentage of monoclonal plasma cells was detected in the bone marrow. The patient received four cycles of VAD and subsequent high-dose chemothera...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 1999-05, Vol.23 (9), p.967-969
Hauptverfasser:	SEZER, O, SCHMID, P, SCHWEIGERT, M, HEIDER, U, EUCKER, J, HARDER, H, SINHA, P, RADTKE, H, POSSINGER, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Amyloidosis Amyloidosis - complications Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts Biological and medical sciences Biopsy Bone marrow Chemotherapy Combined Modality Therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Dexamethasone - therapeutic use Doxorubicin - therapeutic use Edema Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Kidney diseases Light chains Male Medical sciences Melphalan Melphalan - therapeutic use Middle Aged Morbidity Nephrotic syndrome Nephrotic Syndrome - etiology Nephrotic Syndrome - physiopathology Nephrotic Syndrome - therapy Peripheral blood Pharmacology. Drug treatments Plasma cells Proteinuria Recurrence Stem cell transplantation Stem cells Transplantation Transplantation, Autologous Vincristine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!